BE875634A - Compositions pharmaceutiques et leur utilisation pour le traitement prophylactique et therapeutique de l'hyperplasie de la prostate - Google Patents

Compositions pharmaceutiques et leur utilisation pour le traitement prophylactique et therapeutique de l'hyperplasie de la prostate

Info

Publication number
BE875634A
BE875634A BE0/194651A BE194651A BE875634A BE 875634 A BE875634 A BE 875634A BE 0/194651 A BE0/194651 A BE 0/194651A BE 194651 A BE194651 A BE 194651A BE 875634 A BE875634 A BE 875634A
Authority
BE
Belgium
Prior art keywords
prophylactic
pharmaceutical compositions
therapeutic treatment
prostate hyperplasia
hyperplasia
Prior art date
Application number
BE0/194651A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BE875634A publication Critical patent/BE875634A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BE0/194651A 1978-04-17 1979-04-17 Compositions pharmaceutiques et leur utilisation pour le traitement prophylactique et therapeutique de l'hyperplasie de la prostate BE875634A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782817157 DE2817157A1 (de) 1978-04-17 1978-04-17 Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie

Publications (1)

Publication Number Publication Date
BE875634A true BE875634A (fr) 1979-10-17

Family

ID=6037493

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/194651A BE875634A (fr) 1978-04-17 1979-04-17 Compositions pharmaceutiques et leur utilisation pour le traitement prophylactique et therapeutique de l'hyperplasie de la prostate

Country Status (13)

Country Link
US (1) US4310523A (fr)
JP (1) JPS5513261A (fr)
AU (1) AU528179B2 (fr)
BE (1) BE875634A (fr)
CA (1) CA1134271A (fr)
CH (1) CH641679A5 (fr)
DE (1) DE2817157A1 (fr)
GB (1) GB2018591B (fr)
IT (1) IT1119733B (fr)
LU (1) LU81153A1 (fr)
NL (1) NL7901961A (fr)
SE (1) SE441977B (fr)
ZA (1) ZA791797B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
WO1985002543A1 (fr) * 1983-12-12 1985-06-20 Kaszynski Edwin G Modification de la croissance pilaire
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
AU5045690A (en) 1989-01-27 1990-08-24 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5595985A (en) * 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
EP0943328B1 (fr) * 1989-07-07 2004-06-16 Endorecherche Inc. Thérapie combinée dans la prophylaxe et/ou dans le traitement de l'hyperplasie benigne de la prostate
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6743419B1 (en) 1992-12-22 2004-06-01 The Gillette Company Method of reducing hair growth employing sulfhydryl active compounds
US5411991A (en) * 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0729363B1 (fr) * 1994-06-27 2003-02-19 Neutron Therapies Inc. Analogues d'hormone contenant du bore et procedes d'utilisation de ces derniers pour visualiser ou eliminer des cellules pourvues de recepteurs d'hormones
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
JPH11507050A (ja) * 1995-06-07 1999-06-22 メルク エンド カンパニー インコーポレーテッド 前立腺病の処置および予防
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
AU2707999A (en) 1998-03-11 1999-09-27 Endorecherche Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
EP1321146A3 (fr) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibiteurs de la 17beta-hydroxysteroide deshydrogénase du type 5 et du type 3 ainsi que leurs méthodes d'utilisation
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
DE60045751D1 (de) 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
WO2002002099A1 (fr) * 2000-07-05 2002-01-10 Astrazeneca Ab Combinaison pharmaceutique d'un anti-androgene et de tamoxifene pour obtenir un effet anti-androgenique et une inhibition d'aromatase
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US9333190B2 (en) * 2006-11-21 2016-05-10 Jina Pharmaceuticals, Inc. Endoxifen compositions and methods
US8288342B2 (en) * 2008-10-10 2012-10-16 Teva Women's Health, Inc. Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076823A (en) * 1961-07-03 1963-02-05 Syntex Corp Process for the production of 6-chloro-3-keto-deta steroid compounds
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
CH641679A5 (de) 1984-03-15
SE441977B (sv) 1985-11-25
DE2817157A1 (de) 1979-10-25
NL7901961A (nl) 1979-10-19
US4310523A (en) 1982-01-12
LU81153A1 (de) 1979-06-19
JPS645007B2 (fr) 1989-01-27
SE7903240L (sv) 1979-10-18
GB2018591B (en) 1982-09-08
IT1119733B (it) 1986-03-10
AU528179B2 (en) 1983-04-21
ZA791797B (en) 1980-11-26
CA1134271A (fr) 1982-10-26
IT7921854A0 (it) 1979-04-13
GB2018591A (en) 1979-10-24
AU4560479A (en) 1979-10-25
JPS5513261A (en) 1980-01-30

Similar Documents

Publication Publication Date Title
BE875634A (fr) Compositions pharmaceutiques et leur utilisation pour le traitement prophylactique et therapeutique de l'hyperplasie de la prostate
BE854414A (fr) Compositions pharmaceutiques pour le traitement de l'hypertrophie benigne de la prostate
BE890522A (fr) Composition prophylactique et therapeutique pour l'hyperplasie de la prostate et son utilisation
BE851328A (fr) Composition pour le traitement de l'hypercholesterolemie
BE884917A (fr) Agent pour le traitement de theilerioses et son application
BE876157Q (fr) Medicament pour le traitement de l'acne
BE889327A (fr) Preparations pharmaceutiques a base de peroxydes et d'erythromycines pour le traitement topique de l'acne
BE890521A (fr) Composition prophylactique et therapeutique pour l'hyperplasie de la prostate et son utilisation
BE854416A (fr) Compositions pharmaceutiques pour le traitement des symptomes de la menopause et leur procede d'utilisation
BE865156A (fr) Compositions pharmaceutiques pour le traitement des depressions
BE890433A (fr) Composition cosmetique pour le traitement local de la cellulite
BE881208A (fr) Composition pharmaceutique pour le traitement de psoriasis et methode d'utilisation de celle-ci
BE887639A (fr) Compositions pharmaceutiques pour le traitement de l'hyperplasie prostatique benigne
BE829859A (fr) Procedes et compositions pharmaceutiques pour le traitement de l'hypercholesterolemie
FR2499407B1 (fr) Composition pharmaceutique et son application therapeutique pour le traitement des maladies de la cavite buccale
FR2612775B1 (fr) Compositions pour la prevention et le traitement de la degenerescence cutanee
BE852095A (fr) Composition pharmaceutique pour le traitement de la leucemie et de tumeurs
BE885290A (fr) Compositions pharmaceutiques pour le traitement des hyperlipidemies et des hyperlipoproteinemies
BE885291A (fr) Compositions pharmaceutiques pour le traitement des dysfonctionnements cardiaques
BE872908A (fr) Compositions pharmaceutiques pour le traitement de l'hypertension
BE854137A (fr) Composition pharmaceutiques de traitement de l'acne
FR2310769A1 (fr) Medicament pour le traitement de l'alopecia seborrhoeica
BE871753A (fr) Nouvelle utilisation therapeutique de l'acetyl-1-carnitine pour le traitement des affections cardiaques
BE860992A (fr) Composition et tampon pour le traitement ou la prevention de l'acne et d'affections de la peau similaires
FR2340737A1 (fr) Composition pour le traitement de l'hypercholesterolemie

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: SCHERING A.G.

Effective date: 19920430